TickerTalks
Browse all tickers →
TickerTalks›$ISRG
ISISRG

Intuitive Surgical, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 23% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (1.2K/wk), no spike
$ISRG·$151B·Medical - Devices·Healthcare
$345.42-14.1%YTD-39.1%1Y-33.1%
Mentions · last 7 days
2026-07-10: 202 posts2026-07-11: 69 posts2026-07-12: 154 posts2026-07-13: 258 posts2026-07-14: 123 posts2026-07-15: 132 posts2026-07-16: 270 posts1,226-2%
Price updated 5h ago·X counts updated 1d ago
ISISRG
$ISRGIntuitive Surgical, Inc.
$345.42-14.15%1.2k posts-2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ISRG, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-17

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Robotic-surgery leader just beat Q2 with the stock still at 11% of its 52-week range — a real setup.

Intuitive Surgical makes the da Vinci robotic-surgery systems that dominate general and gynecologic-surgery workflows in US hospitals, plus the Ion robotic bronchoscopy platform. It's the archetypal quality med-tech compounder that had a rough 2026 on tariff/China concerns and elective-procedure volatility.

Why the setup is genuinely interesting:

  • Growth remains excellent: Q1 revenue up 23% YoY to $2.77B, and the four-quarter growth stack is 21-23% — this is a business still growing in the low twenties despite the multiple compression.
  • Q2 just beat estimates: today's Reuters/Zacks read on 'strong demand for robotic systems' plus a beat-and-beat print restarts the compounder narrative that had been left for dead.
  • The multiple has reset from the highs: 50x trailing earnings and 39x FY27 consensus EPS of $10.44 — still not cheap, but a real reset from the peak-premium that used to be paid for ISRG.
  • The tape has confirmed the reset AND the beat: shares at 11% of the 52-week range with today's +3.4% moving off the lows, but the stock is still 17% below its 200-day moving average — the pattern of a base being tested rather than confirmed.
  • Insider action is one director's small F-InKind tax withholding, not a signal — consistent with a company where the management team is watching the multiple reset rather than distributing into it.

The forward view: with earnings just landed and next print not until October 20, the near-term tape is a function of positioning (real active-manager flows re-entering after the beat) and any commentary on the Chinese hospital demand environment. What restarts the compounder: continued beat-and-raise pattern combined with a Citi 90-day upside catalyst-call follow-through. What keeps it coiled: another tariff/China escalation, or a specific da Vinci system placement slowdown. What could break it lower: a competitive display from Medtronic Hugo or Johnson & Johnson Ottava that shows real market-share erosion.

Agrees with X sentimentThe bullish X read on Citi's catalyst-call, physical-AI-trade framing, and the quality-watchlist positioning matches the setup. Our take agrees the beat is the referee event and the crowd is right to be constructive — the only caveat is the current tape is a coil, not a confirmed break.

What to watch: October 20 Q3 earnings and any tariff/China commentary between now and then; a Medtronic Hugo or J&J Ottava competitive-win headline would break the coil lower.

On the calendar: 2026-10-20 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment31 posts analyzed · as of 2026-07-17

Intuitive Surgical delivered a headline double beat: Q2 revenue of $2.89B on 19% YoY growth, adjusted EPS of $2.80 versus $2.51 (up 28% YoY), non-GAAP operating margin of 42%, 400+ new da Vinci systems installed. Full-year guidance was left unchanged. Despite the print, the stock fell as much as 10-13% after-hours to a fresh 52-week low near $360, roughly -39% from its high. The dominant bear thread is that da Vinci procedure growth slowed to a four-year low, that Chinese competitive pressure is override the clean numbers, and that HCA Healthcare's reduced earnings outlook is dragging the whole surgical-robotics tape. Bulls call the reaction an overreaction and see sub-30x forward earnings as attractive.

Read the AI verdict + X sentiment for $ISRG

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes the da Vinci robotic surgery system, earning recurring revenue from instruments and service contracts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $ISRG.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

What this means for $ISRG

Partial — Makes the da Vinci robotic surgery system, earning recurring revenue from instruments and service contracts; the surgical robotics procedure growth and AI-enabled device adoption creates tailwinds for one product line, not the full operation.

Industry benchmark

13-name peer basket
-11.1%YTD
-3.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
50.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
16.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
30.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
14.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
17.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
66.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 16, 2026$2.80$2.48+12.9%
Q1 2026Apr 21, 2026$2.80$2.51+11.6%
Q4 2025Jan 22, 2026$2.53$2.27+11.5%
Q3 2025Oct 21, 2025$2.40$1.99+20.6%
Next earningsTue, Oct 20·consensus EPS $2.59

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.8B+23.0%66.1%30.9%$2.31$808.6M
Q4 FY25$2.9B+18.8%66.4%30.2%$2.24$730.0M
Q3 FY25$2.5B+22.9%66.4%30.3%$1.98$735.6M
Q2 FY25$2.4B+21.4%66.3%30.5%$1.84$560.1M

Forward consensus

5-year forecast · up to 25 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.7B$11.4B – $12.4B$10.44$10.17 – $10.6424
FY27$13.3B$12.8B – $13.6B$11.84$11.46 – $12.3125
FY28$15.1B$15.1B – $15.2B$13.43$11.79 – $14.6124
FY29$17.2B$16.6B – $18.0B$15.65$15.03 – $16.6523
FY30$18.7B$18.2B – $19.7B$17.07$16.41 – $18.1715

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.4.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-17.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-29.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 352.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 12Mark BrosiusEVP & Chief Mfg and Supply Cha25 sh$10KSellJun 11Mark BrosiusEVP & Chief Mfg and Supply Cha23 sh$9KSellJun 10Mark BrosiusEVP & Chief Mfg and Supply Cha23 sh$10KSellJun 10Gary LoebEVP & Chief Legal and Complian400 sh$170KSellJun 9Mark BrosiusEVP & Chief Mfg and Supply Cha23 sh$10KSellJun 8Mark BrosiusEVP & Chief Mfg and Supply Cha23 sh$10KSellJun 1Iman JeddiSVP & GM da Vinci Platforms &5.6K sh$2.4MSellMay 22Mark BrosiusEVP & Chief Mfg and Supply Cha18 sh$8KSellMay 21Mark BrosiusEVP & Chief Mfg and Supply Cha18 sh$8KSellMay 20Mark BrosiusEVP & Chief Mfg and Supply Cha18 sh$8K
1–10 of 25
+ 29 other (16 exempts · 9 awards · 4 inkinds) in window

See when $ISRG insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change
AI summary

Intuitive Surgical, Inc. announced that Henry L. Charlton will transition from his role as Chief Commercial and Marketing Officer to Senior Vice President of Global Business Operations effective July 1, 2026. Taylor Patton, currently Global SVP Endoluminal, will succeed Charlton as the Company's new Chief Commercial and Marketing Officer. The leadership change appears to be an orderly internal transition with no indication of disagreement, and reflects the company's continued commercial expansion in surgical robotics.

8-KOfficer or director changeMay 48-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote · Item 7.01: Press release / Reg FD
AI summary

ISRG disclosed a personnel change (8-K Item 5.02, dated 2026-05-04). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

3New insider — initial holdingsFeb 53
3New insider — initial holdingsFeb 53
+ 11 other (2 13Gs · 2 earnings 8-Ks · 2 proxys · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Intuitive Surgical Q2: The Market Is Missing The Bigger Pictureseekingalpha.com·7h agoWhy Intuitive Surgical Stock Plunged Todayinvestopedia.com·10h agoISRG Q2 Earnings Beat Estimates, Stock Falls on Slow Procedure Growthzacks.com·12h agoIntuitive Surgical Stock Sinks to 52-Week Low - Here's Whybenzinga.com·13h ago3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdleszacks.com·16h ago

In themes

Explore the broader themes this ticker is being talked about under.

Robotics & Humanoids

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABT$BSX$BFLY$TMDX$BIO$ECOR$PRCT$CLPT
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport